- Home
- DHY vs OABI Comparison
DHY vs OABI Comparison
Compare DHY & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- OABI
- Stock Information
- Founded
- DHY 1998
- OABI 2012
- Country
- DHY United States
- OABI United States
- Employees
- DHY N/A
- OABI N/A
- Industry
- DHY Finance/Investors Services
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- OABI Health Care
- Exchange
- DHY Nasdaq
- OABI Nasdaq
- Market Cap
- DHY 220.7M
- OABI 228.9M
- IPO Year
- DHY N/A
- OABI N/A
- Fundamental
- Price
- DHY $2.09
- OABI $1.64
- Analyst Decision
- DHY
- OABI Strong Buy
- Analyst Count
- DHY 0
- OABI 3
- Target Price
- DHY N/A
- OABI $6.67
- AVG Volume (30 Days)
- DHY 569.1K
- OABI 419.6K
- Earning Date
- DHY 01-01-0001
- OABI 11-11-2025
- Dividend Yield
- DHY 9.10%
- OABI N/A
- EPS Growth
- DHY N/A
- OABI N/A
- EPS
- DHY N/A
- OABI N/A
- Revenue
- DHY N/A
- OABI $23,027,000.00
- Revenue This Year
- DHY N/A
- OABI N/A
- Revenue Next Year
- DHY N/A
- OABI $44.99
- P/E Ratio
- DHY N/A
- OABI N/A
- Revenue Growth
- DHY N/A
- OABI 6.05
- 52 Week Low
- DHY $1.77
- OABI $1.22
- 52 Week High
- DHY $2.08
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- DHY 43.26
- OABI 43.98
- Support Level
- DHY $2.07
- OABI $1.55
- Resistance Level
- DHY $2.11
- OABI $1.73
- Average True Range (ATR)
- DHY 0.02
- OABI 0.10
- MACD
- DHY 0.00
- OABI 0.00
- Stochastic Oscillator
- DHY 50.00
- OABI 30.59
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.